Interplay Among Gut Microbiota-Derived TMAO, Autonomic Nervous System Dysfunction, and Heart Failure Progression

Area of Science:

• Microbiology
• Cardiovascular Science
• Neuroscience

Background:

• Gut microbiota plays a vital role in metabolic and cardiovascular health.
• Dysbiosis disrupts the gut-brain-heart axis, leading to neuroinflammation and impaired cardiac function.
• Reduced cerebral perfusion exacerbates this dysfunction.

Purpose of the Study:

• To review how cardiac autonomic control is modulated by gut microbiota and its byproducts, specifically Trimethylamine-N-oxide (TMAO).
• To highlight TMAO as a potential therapeutic target for heart failure (HF) prevention and treatment.

Main Methods:

• Literature review focusing on the mechanistic links between gut microbiota, TMAO, and cardiovascular dysfunction.
• Analysis of clinical evidence associating TMAO with HF outcomes.
• Exploration of novel therapeutic strategies targeting the microbiota-TMAO axis.

Main Results:

• Elevated TMAO levels, derived from dietary precursors, are associated with atherosclerosis and heart failure.
• TMAO contributes to cardiovascular disease by activating inflammatory pathways (NLRP3 inflammasome), inhibiting protective mechanisms (SIRT3-SOD2), and increasing platelet reactivity.
• TMAO influences the autonomic nervous system, promoting sympathetic activity and cardiac arrhythmias, and is a predictor of mortality in HF.

Conclusions:

• Directly targeting the gut microbiota and TMAO represents a novel therapeutic avenue for cardiovascular diseases, particularly HF.
• Integrating TMAO assessment into risk models and utilizing advanced research models are crucial for personalized cardiovascular interventions.